Invention Grant
- Patent Title: P aeruginosa PcrV-linked antigen vaccines
-
Application No.: US15769646Application Date: 2016-10-19
-
Publication No.: US11406696B2Publication Date: 2022-08-09
- Inventor: Christiane Marie-Paule Simone Jeanne Feron , Stefan Jochen Kemmler , Michael Thomas Kowarik , Julien Laurent Quebatte
- Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
- Applicant Address: BE Rixensart
- Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
- Current Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
- Current Assignee Address: BE Rixensart
- Agent Dana L. Broughton
- Priority: GB1518668 20151021
- International Application: PCT/EP2016/075048 WO 20161019
- International Announcement: WO2017/067964 WO 20170427
- Main IPC: A61K39/02
- IPC: A61K39/02 ; A61K39/104 ; A61K39/385 ; C07K14/21 ; A61K47/64 ; A61K45/06 ; A61P31/04 ; C12N9/10 ; A61K39/00
Abstract:
The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.
Public/Granted literature
- US20190091319A1 P AERUGINOSA PCRV-LINKED ANTIGEN VACCINES Public/Granted day:2019-03-28
Information query
